Citations

Clear

6274 citation(s) found for "To, Andrew".

The Interaction between HLA‐DRB1 and Smoking in Parkinson's Disease Revisited
Domenighetti, Cloé , Douillard, Venceslas , Sreelatha, Ashwin Ashok Kumar , Schulte, Claudia , Grover, Sandeep , May, Patrick , Radivojkov‐Blagojevic, Milena , Lichtner, Peter , Singleton, Andrew B., Hernandez, Dena G., Edsall, Connor , Mellick, George D. , Zimprich, Alexander , Pirker, Walter , Kõks, Sulev, Lesage, Suzanne , Chartier‐Harlin, Marie‐Christine , Brockmann, Kathrin , Deutschländer, Angela , Hadjigeorgiou, G., Dardiotis, Efthimos, Simitsi, Athina Maria, Petrucci, Simona , Straniero, Letizia , Pezzoli, Gianni , Brighina, Laura , Ferrarese, Carlo , Annesi, Grazia , Quattrone, Andrea , Gagliardi, Monica , Nakayama, Akiyoshi , Kim, Yun Joong , Kolber, Pierre, Warrenburg, Bart P.C. van de , Bloem, Bastiaan R. , Aasly, Jan , Toft, Mathias , Guedes, Leonor Correia , Ferreira, Joaquim J. , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Pástor, Pau , Wirdefeldt, Karin , Ran, Caroline , Puschmann, Andreas , Ygland, Emil , Morrison, Karen , Krainc, Dimitri, Burbulla, Lena F. , Krüger, Rejko , Gasser, Thomas , Sharma, Manu , Vince, Nicolas , Elbaz, Alexis , Schulte, Claudia , Grover, Sandeep , May, Patrick , Bobbili, Dheeraj R , Corvol, Jean-Christophe , Mutez, Eugénie , Brockman, Kathrin , Valente, Enza Maria , Toft, Mathias , Ferreira, Joaquim J , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Tan, Manuela , Sharma, Manu , Elbaz, Alexis , Puschmann, Andreas , Zimprich, Alexander , Pastor, Pau , Koks, Sulev , Domenighetti, Cloé , Sugier, Pierre‐Emmanuel , Bobbili, Dheeraj Reddy , Singleton, Andrew , Gourraud, Pierre‐Antoine , Rogaeva, Ekaterina A. , Lang, Anthony E. , Taba, Pille , Brice, Alexis , Corvol, Jean‐Christophe , Mutez, Eugénie , Stefanis, Leonidas , Simitsi, Athina‐Maria , Valente, Enza Maria , Duga, Stefano , Zecchinelli, Anna , Matsuo, Hirotaka , Hattori, Nobutaka , Nishioka, Kenya , Chung, Sun Ju , Pihlstrøm, Lasse , Carr, Jonathan , Díez-Fairén, Mónica , Pedersen, Nancy L. , Belin, Andrea Carmine , Clarke, Carl E , Krainc, Dimitri , Farrer, Matthew J.

Mayo Clinic

Movement Disorders | July 10, 2022 | Volume: 37 | Issue: 9 | Pages: 1929-1937

10.1002/mds.29133 | PMID 35810454 Get It

AbstractBackgroundTwo studies that examined the interaction between HLA‐DRB1 and smoking in Parkinson's disease (PD) yielded findings in opposite directions.ObjectiveTo perform a large‐scale independent replication of the HLA‐DRB1 × smoking interaction.MethodsWe genotyped 182 single nucleotide polymorphism (SNPs) associated with smoking initiation in 12 424 cases and 9480 controls to perform a Mendelian randomization (MR) analysis in strata defined by HLA‐DRB1.ResultsAt the amino acid level, a valine at position 11 (V11) in HLA‐DRB1 displayed the strongest association with PD. MR showed an inverse association between genetically predicted smoking initiation and PD only in absence of V11 (odds ratio, 0.74, 95% confidence interval, 0.59–0.93, PInteraction = 0.028). In silico predictions of the influence of V11 and smoking‐induced modifications of α‐synuclein on binding affinity showed findings consistent with this interaction pattern.ConclusionsDespite being one of the most robust findings in PD research, the mechanisms underlying the inverse association between smoking and PD remain unknown. Our findings may help better understand this association. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
A Rare Case of Idiopathic Systemic Capillary Leak Syndrome
Malla, Shelina, Pawar, Tushar, Tharu, Biswaraj , Basnet, Sijan , Rettew, Andrew , Forman, Daniel, Malla, Shelina

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | July 9, 2022 | Volume: 12 | Issue: 4 | Pages: 108-111

10.55729/2000-9666.1083 | PMID 36262911 Get It

Idiopathic systemic capillary leak syndrome (SCLS) is characterized by an increased capillary hyperpermeability with subsequent hemoconcentration, hypoproteinemia, and hypovolemia. Patients present with diffuse swelling, weight gain, low blood pressure, and shock. We present our case of idiopathic SCLS in a 50-year-old man presenting with prodromal flu-like illness associated with shock that was complicated by compartment syndrome requiring four limb fasciotomies, disseminated intravascular coagulation, acute kidney injury requiring dialysis, and cardiac arrest.
Reconstruction of oral cavity defects using myogenous‐only scapular tip free‐flaps
Barton, Blair M. , Pappa, Andrew K. , Blumberg, Jeffrey M. , Patel, Samip , Patel, Samip N

Mayo Clinic

Laryngoscope Investigative Otolaryngology | July 8, 2022 | Volume: 7 | Issue: 4 | Pages: 955-962

10.1002/lio2.848 | PMID 36000052 Get It

AbstractBackgroundOral cavity reconstruction is very challenging anatomical subsite to reconstruct. Large defects often require free tissue reconstruction to provide the best chance of form and function. Additionally, free tissue reconstruction aids to prevent fistula formation. We aimed to determine outcomes of oral cavity defect reconstruction using scapular tip free flaps with a myogenous intraoral component.MethodsAll patients with a mandibular or maxillary bony defect that included a disruption of the intraoral mucosa component between 07/1/14 and 07/31/17. Patients were reconstructed with a scapular tip free flap, which included a muscular component that was used to recreate the oral mucosa. The primary study outcomes were flap success rates, development of orocutaneous or oronasal fistula, rate of resuming oral diet as well as the occurrence of medical and surgical complications in the first month following surgery. The tested hypothesis was formulated before data collection began.ResultsTwenty‐five patients were identified by the study criteria. There was one (4%) flap that failed, while orocutaneous fistula occurred in two patients (8%). Prior history of osteoradionecrosis was a statistically significant predictor of overall complication (p < .05).ConclusionsIntraoral myogenous reconstruction allows for re‐mucosalization of the oral cavity defect and is associated with high viability and low‐complication rates. In patients with amenable oral mucosal defects, a myogenous scapular tip free flap is a suitable reconstructive option.
Race, rituximab, and relapse in TTP
Antun, Ana G., Farland, Andrew M., Metjian, Ara , Park, Yara A. , Ridder, Gustaaf de, Gibson, Briana, Kasthuri, Raj S. , Akwaa, Frank, Clover, Todd, Upreti, Harsh Vardhan , Liu, Angela , Gangaraju, Radhika , Zheng, X. Long , Masias, Camila , Johnson, Andrew D. , Davis, Elizabeth E. , Evans, Michael D. , Mazepa, Marshall , Metjian, Ara , Kasthuri, Raj S , Baumann Kreuziger, Lisa , Sridharan, Meera , McCrae, Keith R , Lim, Ming Y , Zheng, X Long , Raval, Jay S , Evans, Michael D , Mazepa, Marshall A , Chaturvedi, Shruti , Woods, Ryan, Liles, Darla , Kreuziger, Lisa Baumann , Sadler, J. Evan , Sridharan, Meera , Go, Ronald S. , McCrae, Keith R. , Raval, Jay S. , Cataland, Spero R. , Davis, Elizabeth

Mayo Clinic

Blood | July 7, 2022 | Volume: 140 | Issue: 12 | Pages: 1335-1344

10.1182/blood.2022016640 | PMID 35797471 Get It

Abstract Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial disparities in iTTP outcome and response to therapy have not been studied. Using the United States Thrombotic Microangiopathies Consortium iTTP Registry, we evaluated the impact of race on mortality and relapse-free survival (RFS) in confirmed iTTP in the United States from 1995 to 2020. We separately examined the impact of rituximab therapy and presentation with newly diagnosed (de novo) or relapsed iTTP on RFS by race. A total of 645 participants with 1308 iTTP episodes were available for analysis. Acute iTTP mortality did not differ by race. When all episodes of iTTP were included, Black race was associated with shorter RFS (hazard ratio [HR], 1.60; 95% CI, 1.16-2.21); the addition of rituximab to corticosteroids improved RFS in White (HR, 0.37; 95% CI, 0.18-0.73) but not Black patients (HR, 0.96; 95% CI, 0.71-1.31). In de novo iTTP, rituximab delayed relapse, but Black patients had shorter RFS than White patients, regardless of treatment. In relapsed iTTP, rituximab significantly improved RFS in White but not Black patients. Race affects overall relapse risk and response to rituximab in iTTP. Black patients may require closer monitoring, earlier retreatment, and alternative immunosuppression after rituximab treatment. How race, racism, and social determinants of health contribute to the disparity in relapse risk in iTTP deserves further study.
Risk factors for breast cancer–related lymphedema in patients undergoing 3 years of prospective surveillance with intervention
Koelmeyer, Louise , Gaitatzis, Katrina , Dietrich, Mary S. , Shah, Chirag , Boyages, John , McLaughlin, Sarah A. , Taback, Bret , Stolldorf, Deonni P. , Hughes, Michael , French, James , Ngui, Nicholas , Hsu, Jeremy , Moore, Andrew , Ridner, Sheila H. , Koelmeyer, Louise A , Shah, Chirag S , Ridner, Sheila H , Elder, Elisabeth Edström , Moore, Andrew

Mayo Clinic

Cancer | July 7, 2022 | Volume: 128 | Issue: 18 | Pages: 3408-3415

10.1002/cncr.34377 | PMID 35797441 Get It

BackgroundTo evaluate risk factors (treatment‐related, comorbidities, and lifestyle) for breast cancer–related lymphedema (BCRL) within the context of a Prospective Surveillance and Early Intervention (PSEI) model of care for subclinical BCRL.MethodsThe parent randomized clinical trial assigned patients newly diagnosed with breast cancer to PSEI with either bioimpedance spectroscopy (BIS) or tape measurement (TM). Surgical, systemic and radiation treatments, comorbidities, and lifestyle factors were recorded. Detection of subclinical BCRL (change from baseline of either BIS L‐Dex ≥6.5 or tape volume ≥ 5% and < 10%) triggered an intervention with compression therapy. Volume change from baseline ≥10% indicated progression to chronic lymphedema and need for complex decongestive physiotherapy. In this secondary analysis, multinomial logistic regressions including main and interaction effects of the study group and risk factors were used to test for factor associations with outcomes (no lymphedema, subclinical lymphedema, progression to chronic lymphedema after intervention, progression to chronic lymphedema without intervention). Post hoc tests of significant interaction effects were conducted using Bonferroni‐corrected alphas of .008; otherwise, an alpha of .05 was used for statistical significance.ResultsThe sample (n = 918; TM = 457; BIS = 461) was female with a median age of 58.4 years. Factors associated with BCRL risk included axillary lymph node dissection (ALND) (p < .001), taxane‐based chemotherapy (p < .001), regional nodal irradiation (RNI) (p ≤ .001), body mass index >30 (p = .002), and rurality (p = .037). Mastectomy, age, hypertension, diabetes, seroma, smoking, and air travel were not associated with BCRL risk.ConclusionsWithin the context of 3 years of PSEI for subclinical lymphedema, variables of ALND, taxane‐based chemotherapy, RNI, body mass index >30, and rurality increased risk.
Clinical Reasoning: A 43-Year-Old Man With Subacute Onset of Vision Disturbances, Jaw Spasms, and Balance and Sleep Difficulties
Orozco, Emma, Guo, Yong , Chen, John J. , Dubey, Divyanshu , Howell, Bradley, Moutvic, Margaret A., Louis, Erik K. St. , Moutvic, Margaret, St Louis, Erik K, St Louis, E K , Chen, John J , Dubey, Divyanshu , McKeon, Andrew

Mayo Clinic

Neurology | July 6, 2022 | Volume: 99 | Issue: 9 | Pages: 387-392

10.1212/wnl.0000000000200950 | PMID 35794020 Get It

Association of outpatient use of renin–angiotensin–aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study
Jeffery, Molly M. , Silva, Lucas Oliveira J. e , Bellolio, Fernanda , Jeffery, Molly Moore , Oliveira J E Silva, Lucas , Dempsey, Timothy M , Limper, Andrew, Bellolio, M Fernanda , Garovic, Vesna D. , Dempsey, Timothy , Limper, Andrew H. , Cummins, Nathan W.

Mayo Clinic

BMJ Open | July 6, 2022 | Volume: 12 | Issue: 7 | Pages: e060305

10.1136/bmjopen-2021-060305 | PMID 35793915 Get It

Objectives Evaluate the associations between patients taking ACE inhibitors and angiotensin receptor blockers (ARBs) and their clinical outcomes after an acute viral respiratory illness (AVRI) due to COVID-19. Design Retrospective cohort. Setting The USA; 2017–2018 influenza season, 2018–2019 influenza season, and 2019–2020 influenza/COVID-19 season. Participants People with hypertension (HTN) taking an ACEi, ARB or other HTN medications, and experiencing AVRI. Main outcome measures Change in hospital admission, intensive care unit (ICU) or coronary care unit (CCU), acute respiratory distress (ARD), ARD syndrome (ARDS) and all-cause mortality, comparing COVID-19 to pre-COVID-19 influenza seasons. Results The cohort included 1 059 474 episodes of AVRI (653 797 filled an ACEi or ARB, and 405 677 other HTN medications). 58.6% were women and 72.9% with age ≥65. The ACEi/ARB cohort saw a larger increase in risk in the COVID-19 influenza season than the other HTN medication cohort for four out of five outcomes, with an additional 1.5 percentage point (pp) increase in risk of an inpatient stay (95% CI 1.2 to 1.9 pp) and of ICU/CCU use (95% CI 0.3 to 2.7 pp) as well as a 0.7 pp (0.1 to 1.2 pp) additional increase in risk of ARD and 0.9 pp (0.4 to 1.3 pp) additional increase in risk of ARDS. There was no statistically significant difference in the absolute risk of death (−0.2 pp, 95% CI −0.4 to 0.1 pp). However, the relative risk of death in 2019/2020 versus 2017/2018 for the ACEi/ARB group was larger (1.40 (1.36 to 1.44)) than for the other HTN medication cohort (1.24 (1.21 to 1.28)). Conclusions People with AVRI using ACEi/ARBs for HTN had a greater increase in poor outcomes during the COVID-19 pandemic than those using other medications to treat HTN. The small absolute magnitude of the differences likely does not support changes in clinical practice.
Effects on physiologic measures of appetite from intragastric balloon and endoscopic sleeve gastroplasty: results of a prospective study
Rapaka, Babusai , Maselli, Daniel B. , López-Nava, Gontrand, Bautista-Castaño, Inmaculada , Jaruvongvanich, Veeravich , Matar, Reem , Vargas, Eric J. , Storm, Andrew C. , Acosta, Andrés , Dayyeh, Barham K. Abu

Mayo Clinic

Chinese Medical Journal | July 5, 2022 | Volume: 135 | Issue: 10 | Pages: 1234-1241

10.1097/cm9.0000000000002097 | PMID 35788090 Get It

Abstract Background: Endoscopic bariatric therapies can help address widening management gaps in obesity. Their ability to facilitate weight loss is largely tied to influences on appetite through perturbations of gastric emptying and accommodation. As these tools gain traction in obesity therapy, their physiologic underpinnings require exploration, which may enhance efficacy, tolerance, and patient-tailored care. Methods: We prospectively assessed consecutive subjects with fluid-filled intragastric balloons (IGBs) (n = 18) placed between October 2016 and June 2017 or underwent endoscopic sleeve gastroplasty (ESG) (n = 23) from March 2018 to June 2018. Patients underwent physiologic appraisal at 3 months with 13C-spirulina-based gastric emptying breath test to determine time to half emptying (T50), as well as maximum tolerated volume (MTV) of a standard nutrient drink test. Changes in T50 and MTV at 3 months were compared with percent total body weight loss (%TBWL) at 3 and 6 months using best-fit linear regression. Results: The change in T50 at 3 months correlated with %TBWL at 3 months for IGB (P = 0.01) and ESG (P = 0.01) but with greater impact on %TBWL in IGB compared to ESG (R 2 = 0.42 vs. 0.26). Change in T50 at 3 months was predictive of weight loss at 6 months for IGB (P = 0.01) but not ESG (P = 0.11). ESG was associated with greater decrease in MTV compared to IGB (340.25 ± 297.97 mL vs. 183.00 ± 217.13 mL, P = 0.08), indicting an enhanced effect on satiation through decreased gastric accommodation. Changes in MTV at 3 months did not correlate with %TBWL for either IGB (P = 0.26) or ESG (P = 0.49) but trended toward significance for predicting %TBWL at 6 months for ESG (P = 0.06) but not IGB (P = 0.19). Conclusion: IGB and ESG both induce weight loss but likely through distinct gastric motor function phenotypes, and gastric emptying may predict future weight loss in patients with IGB.